Biodegradable implants for ocular delivery of anti-inflammatory drug

Journal of Drug Delivery Science and Technology

Volumn 17, Issue 1, 2007, Pages 93-97

  Fialho, S L ^a   Siqueira, R C ^b   Jorge, R ^c   Silva Cunha, A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CERV Retina and Vetreous Specialized Center   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biodegradable intraocular implant; Dexamethasone; In vitro release; In vivo release; Toxicity; Trocar

Indexed keywords

ANTIINFLAMMATORY AGENT; DEXAMETHASONE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE; MALE; NONHUMAN; RABBIT; RETINA; VITREOUS BODY;

EID: 33847367658     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(07)50013-4     Document Type: Article

References (37)

1. Peyman G.A., Ganiban G.J. - Delivery systems for intraocular routes. - Adv. Drug Deliv. Rev., 16, 107-123, 1995.
2. Yasukawa T., Ogura Y., Tabata Y., Kimura H., Wiedemann P., Honda Y. - Drug delivery systems for vitreoretinal diseases. - Prog. Retin. Eye Res., 23, 253-281, 2004.
3. Hida T., Chandler D., Arena J.E., Machemer R. - Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. - Am. J. Ophthalmol., 101, 190-195, 1986.
4. Behar-Cohen F. - Systèmes de délivrance des médicaments pour le segment antérieur:bases fondamentales et applications cliniques. - J. Fr. Ophtalmol., 25, 537-544, 2002.
5. Velez G., Whitcup S.M. - New developments in sustained release drug delivery for the treatment of intraocular disease. - Br. J. Ophthalmol., 83, 1225-1229, 1999.
6. Sanborn G.E., Anand R., Torti R.E., Nightingale S.D., Cal S.X., Yates B., Ashton P., Smith T. - Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. - Arch. Ophthalmol., 110, 188-195, 1992.
7. Yang C.S., Khawly J.A., Hainsworth D.P., Chen S.N., Ashton P., Guo H., Jaffe G.J. - An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug inthe treatment of experimental proliferative vitreoretinopathy. - Arch. Ophthalmol., 116, 69-77, 1998.
8. Tan D.T.H., Chee S., Lim L., Lim A.S. - Randomized clinical trial of a new dexamethasone delivery system (surodex) for treatment of postcataract surgery inflammation. - Ophthalmology, 106, 223-231, 1999.
9. Jaffe G.J., Ben-Nun J., Guo H., Dunn J.P., Ashton P. - Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. - Ophthalmology, 107, 2024-2033, 2000.
10. Hashizoe M., Ogura Y., Kimura H., Moritera T., Honda Y., Kyo M., Hyon S.H., Ikada Y. - Scleral plug of biodegradable polymers for controlled drug release in the vitreous. - Arch. Ophthalmol., 112, 1380-1384, 1994.
11. Kimura H., Ogura Y., Hashizoe M., Nishiwaki H., Honda Y., Ikada Y. - A new vitreal drug delivery system using an implantable biodegradable polymeric device. - Invest. Ophthalmol. Vis. Sci., 35, 2815-2819, 1994.
12. Zhou T., Lewis H., Foster R.E., Schwendeman S.P. - Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. - J. Control. Release, 55, 281-295, 1998.
13. Tan D.T.H., Chee S.P., Lim L., Theng J., Van Ede M. - Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery : anterior versus posterior placement of two surodex in the eye. - Ophthalmology, 108, 2172-2181, 2001.
14. Morita Y., Ohtori A., Kimura M., Tojo K. - Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. - Biol. Pharm. Bull., 21, 188-190, 1998.
15. Penfold P.L., Wen L., Madigan M.C., Gillies M.C., King N.J., Provis J.M. - Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. - Clin. Exp. Immunol., 121, 458-465, 2000.
16. Singer K.L., Stevenson B.R., Woo P.L., Firestone G.L. - Relationship of serine/threonine phosphorylation/dephosphorylation signaling to glucocorticoid regulation of tight junction permeability and ZO-1 distribution in nontransformed mammary epithelial cells. - J. Biol. Chem., 269, 16108-16115, 1994.
17. Peyman G.A., Moshfeghi D.M. - Intravitreal triamcinolone acetonide [Editorial]. - Retina, 24, 488-490, 2004.
18. Okabe J., Kimura H., Kunou N., Okabe K., Kato A., Ogura Y. - Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate. - Invest. Ophthalmol. Vis. Sci., 44, 740-744, 2003.
19. Kimura H., Ogura Y. - Biodegradable polymers for ocular drug delivery. - Ophthalmologica, 215, 143-155, 2001.
20. Jain R.A. - The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. - Biomaterials, 21, 2475-2490, 2000.
21. Fialho S.L., Rêgo M.B., Siqueira R.C., Jorge R., Haddad A., Rodrigues A.L., Maia-Filho A., Silva-Cunha A. - Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes - Curr. Eye Res., 31, 525-534, 2006.
22. Fialho S.L., Silva-Cunha A. - Manufacturing techniques of biodegradable implants intended to intraocular application. - Drug Deliv., 12, 109-116, 2005.
23. th ed., NF19. (USP 24) Rockville: United States Pharmacopoeial Convention, 2000. CD-ROM (Insight Publishing Productivity).
24. Culpepper J.A., Lee F. - Regulation of IL 3 expression by glucocorticoids in cloned murine T lymphocytes. - J. Immunol., 135, 3191-3197, 1985.
25. Lewis G.D., Campbell W.B., Johnson A.R. - Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. - Endocrinology, 119, 62-69, 1986.
26. Grabstein K., Dower S., Gills S., Urdal D., Larsen A. - Expression of interleukin 2, interferon-γ, and the IL 2 receptor by human peripheral blood lymphocytes. - J. Immunol., 136, 4503-4508, 1986.
27. Knudsen P.J., Dinarello C.A., Strom T.B. - Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. - J. Immunol., 139, 4129-4134, 1987.
28. Lee S.W., Tsou A.P., Chan H., Thomas J., Petrie K., Eugui E.M., Allison A.C. - Glucocorticoids selectively inhibit the transcription of the interleukin 1 β gene and decrease the stability of interleukin 1 β mRNA. - Proc. Natl. Acad. Sci. USA., 85, 1204-1208, 1988.
29. Dash A.K., Cudworth II G.C. - Therapeutic applications of implantable drug delivery systems. - J. Pharmacol. Toxicol. Methods, 40, 1-12, 1998.
30. Park T.G. - Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition. - Biomaterials, 16, 1123-1130, 1995.
31. Kunou N., Ogura Y., Honda Y., Hyon S.H., Ikada Y. - Biodegradable scierai implant for controlled intraocular delivery of betamethasone phosphate. - J. Biomed. Mater. Res., 51, 635-641, 2000.
32. Friedrich S., Cheng Y.L., Seville B. - Finite element modeling of drug distribution in the vitreous humor of the rabbit eye. - Ann. Biomed. Eng., 25, 303-314, 1997.
33. Tojo K., Isowaki A. - Pharmacokinetic model for in vivo / in vitro correlation of intravitreal drug delivery. - Adv. Drug Deliv. Rev., 52, 17-24, 2001.
34. Martidis A., Duker J.S., Greenberg P.B., Rogers A.H., Puliafito C.A., Reichel E., Baumal C. - Intravitreal triamcinolone for refractory diabetic macular edema. - Ophthalmology, 109, 920-927, 2002.
35. Karacorlu M., Ozdemir H., Karacorlu S. - Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. - Acta. Ophthalmol. Scand., 81, 648-652, 2003.
36. Krepler K., Ergun E., Sacu S., Richter-Muksch S., Wagner J., Stur M., Wedrich A. - Intravitreal triamcinolone acetonide in patients with macular oedema due to central retinal vein occlusion. - Acta. Ophthalmol. Scand., 83, 71-75, 2005.
37. Knepper P., Breen M., Weinstein H., Blacik J. - Intraocular pressure and glycosaminoglycan distribution in the rabbit eye: effect of age and dexamethasone. - Exp. Eye Res., 27, 567-575, 1978.